YOLFTbeta
Aldeyra The

Aldeyra The

ALDX · NASDAQ · Healthcare / Biotechnology

0.6438USD+0.01 (+2.17%)

Price History

Full chart

Market Stats

Previous Close0.6301
Open0.6112
Day Range0.59 – 0.6564
52-Week Range1.07 – 5.93
Volume715.57K
Market Cap73.60M
P/E (TTM)0.00
Forward P/E0.00
EPS-0.35
Dividend Yield0.00%
Beta1.19
50-Day Avg1.52
200-Day Avg2.78

About

Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment of primary vitreoretinal lymphoma and retinitis pigmentosa. The company also develops ADX-629, an orally administered RASP modulator that is in Phase 2 clinical trials for the treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication. In addition, it develops preclinical RASP platforms, including ADX 248, ADX 246, and other novel RASP modulators for the treatment of various diseases associated with RASP. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Todd C. Brady M.D., Ph.D.
  • Employees6
  • Headquarters131 Hartwell Avenue, Lexington, MA, United States, 02421, USA
  • Websitehttps://www.aldeyra.com

Leadership

  • Dr. Todd C. Brady M.D., Ph.D.CEO, President & Director · b. 1972
  • Mr. Michael AlfieriHead of Finance and Principal Financial & Accounting Officer · b. 1965
  • David BurkeHead of Investor Relations
  • Laura NicholsOperations Manager
  • Dr. Adam LazorchakDirector of Translational Sciences & Non-Clinical Development

Financials

Income Statement

Currency: USD2011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue---000000000000
Cost of Revenue---018.78K35.79K37.85K71.00K96.31K56.22K264.18K258.71K262.78K249.62K251.99K
Gross Profit---0-18.78K-35.79K-37.85K-71.00K-96.31K-56.22K-264.18K-258.71K-262.78K-249.62K-251.99K
Operating Expense---7.27M11.97M18.66M22.45M39.63M62.98M36.36M55.96M62.42M42.53M59.87M35.01M
Operating Income-2.11M-1.11M-3.68M-7.27M-11.99M-18.70M-22.49M-39.70M-63.07M-36.42M-56.22M-62.68M-42.79M-60.12M-35.27M
EBITDA-2.10M-22.73M13.22M-4.94M-11.96M-18.56M-22.19M-38.67M-61.44M-34.32M-55.77M-60.07M-35.21M-53.68M-31.69M
Net Income-2.38M-23.07M13.06M-5.19M-12.09M-18.70M-22.34M-38.89M-60.83M-37.55M-57.78M-62.02M-37.54M-55.85M-33.85M
R&D1.36M469.27K1.54M3.71M7.57M13.18M16.30M29.82M44.35M24.68M44.94M47.31M29.46M48.22M25.66M
Interest Expense279.93K342.01K159.32K244.17K112.31K105.51K113.45K146.79K603.85K1.90M1.74M1.69M2.07M1.93M1.91M

Balance Sheet

Currency: USD2011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets258.90K1.98M3.74M8.79M28.20M25.19M44.17M95.09M75.52M83.35M233.14M181.29M148.33M104.61M72.06M
Total Liabilities2.59M27.13M2.13M2.50M3.33M3.54M4.57M8.47M27.44M23.84M27.40M30.28M28.53M33.60M27.81M
Total Equity-2.33M-25.15M-1.90M6.28M24.88M21.65M39.60M86.62M48.08M59.51M205.74M151.01M119.80M71.00M44.25M
Cash250.96K1.22M3.26M8.53M14.65M12.02M20.02M47.36M44.43M77.86M229.79M144.42M142.82M54.53M70.04M
Total Debt2.20M432.92K1.27M1.25M1.29M1.32M1.34M-14.75M15.33M15.86M16.08M15.66M15.30M15.53M
Net Debt1.95M-790.72K-1.99M-7.27M-13.36M-10.70M-18.69M-47.36M-29.67M-62.53M-213.93M-128.34M-127.17M-39.22M-54.51M

Cash Flow

Currency: USD2011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-2.39M-778.05K-1.71M-4.78M-9.31M-15.15M-19.22M-29.86M-44.98M-37.49M-42.56M-56.64M-30.33M-43.21M-33.35M
Investing Cash Flow----14.06K-13.04M-225.23K-10.20M-23.34M18.48M29.02M-7.81K-29.95M30.00M-44.92M47.74M
Financing Cash Flow-1.75M3.75M10.06M28.47M12.74M37.43M80.53M23.58M41.90M194.50M1.22M-1.27M-171.42K1.12M
Capital Expenditure00014.06K86.12K11.81K24.76K262.97K9.53K57.81K16.32K200
Free Cash Flow-2.39M-778.05K-1.71M-4.79M-9.40M-15.16M-19.25M-30.12M-44.99M-37.49M-42.56M-56.65M-30.33M-43.21M-33.35M
Dividends Paid---0000--------
FCF to OCF100.00%100.00%100.00%100.29%100.92%100.08%100.13%100.88%100.02%100.00%100.02%100.03%100.00%100.00%100.00%
Dividend Paid to FCF---0.00%0.00%0.00%0.00%--------

Earnings

Report DateMay 28, 2014Aug 4, 2014Nov 10, 2014Mar 19, 2015May 13, 2015Aug 11, 2015Nov 12, 2015Mar 30, 2016May 9, 2016Aug 10, 2016Nov 14, 2016Mar 30, 2017May 15, 2017Aug 7, 2017Nov 9, 2017Mar 29, 2018May 15, 2018Aug 9, 2018Nov 14, 2018Mar 8, 2019May 9, 2019Aug 8, 2019Nov 7, 2019Mar 12, 2020May 7, 2020Aug 6, 2020Nov 5, 2020Mar 11, 2021May 6, 2021Aug 5, 2021Oct 28, 2021Mar 17, 2022May 5, 2022Aug 5, 2022Nov 10, 2022Mar 9, 2023May 4, 2023Aug 3, 2023Nov 3, 2023Mar 7, 2024May 2, 2024Aug 1, 2024Nov 7, 2024Feb 28, 2025Apr 30, 2025Aug 7, 2025Nov 5, 2025Mar 12, 2026May 7, 2026Aug 13, 2026Nov 4, 2026
EPS Estimate--0.53-0.33-0.40-0.38-0.34-0.32-0.32-0.50-0.44-0.41-0.66-0.34-0.37-0.35-0.32-0.38-0.42-0.47-0.45-0.44-0.49-0.56-0.70-0.48-0.35-0.27-0.28-0.26-0.23-0.25-0.28-0.29-0.30-0.31-0.31-0.28-0.30-0.25-0.14-0.11-0.14-0.26-0.22-0.24-0.21-0.17-0.15-0.12-0.11-0.11
EPS Actual-0.18-0.34-0.36-0.30-0.32-0.27-0.35-0.46-0.51-0.41-0.38-0.37-0.37-0.35-0.32-0.36-0.43-0.46-0.52-0.49-0.58-0.49-0.69-0.48-0.34-0.25-0.23-0.30-0.25-0.28-0.27-0.27-0.29-0.30-0.25-0.22-0.27-0.15-0.14-0.08-0.14-0.28-0.25-0.27-0.17-0.16-0.13-0.11-0.06-0.16-
Surprise-35.85%-9.09%25.00%15.79%20.59%-9.38%-43.75%-2.00%6.82%7.32%43.94%-8.82%5.41%8.57%-12.50%-13.16%-9.52%-10.64%-8.89%-31.82%0.00%-23.21%31.43%29.17%28.57%14.81%-7.14%3.85%-21.74%-8.00%3.57%0.00%0.00%19.35%29.03%3.57%50.00%44.00%42.86%-27.27%-100.00%3.85%-22.73%30.33%23.81%23.53%29.03%50.00%-45.45%-
Timing-Pre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hours-After-hours-After-hours

Key Statistics & Ratios

Market Cap73.60M
Enterprise Value35.89M
Trailing P/E0.00
Forward P/E0.00
PEG Ratio0.00
Price / Sales0.00
Price / Book2.13
EPS-0.35
Book Value0.628
Revenue (TTM)0
Gross Profit (TTM)0
EBITDA-23.80M
Profit Margin0.00%
Operating Margin0.00%
Return on Equity-49.48%
Return on Assets-22.70%
Shares Outstanding60.33M
Shares Float48.95M
Beta1.19
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Strong Buy
Based on 7 analystsTarget 6.60
  • Strong Buy
    5
  • Buy
    2

Ownership Breakdown

Institutions
61.59%
Insiders
3.60%
Retail / Other
34.81%

Top Institutional Holders

  • Knoll Capital Management LP
    5.48M9.08%
  • BlackRock Inc
    3.76M6.24%
  • AQR Capital Management LLC
    2.83M4.69%
  • Kingdon Capital Management LLC
    2.65M4.40%
  • Vanguard Capital Management, LLC
    2.36M3.92%
  • D. E. Shaw & Co LP
    1.94M3.22%
  • 683 Capital Management LLC
    1.50M2.49%
  • Geode Capital Management, LLC
    1.25M2.07%
  • State Street Corp
    1.12M1.86%
  • Ardsley Advisory Partners
    975.00K1.62%
  • Jane Street Group LLC
    968.89K1.61%
  • Renaissance Technologies Corp
    863.19K1.43%
  • Acadian Asset Management LLC
    858.29K1.42%
  • Vanguard Portfolio Management, LLC
    807.78K1.34%
  • Jacobs Levy Equity Management, Inc.
    796.82K1.32%
  • The Goldman Sachs Group Inc
    543.15K0.90%
  • UBS Group AG
    537.57K0.89%
  • Dimensional Fund Advisors, Inc.
    529.08K0.88%
  • Morgan Stanley - Brokerage Accounts
    518.64K0.86%

Top Fund Holders

  • Vanguard MStar Total Stk Mkt Idx Invest
    1.78M2.96%